Hair counts a significant role in shaping the personality of a person. It also plays a very important role in carving the self-esteem of an individual. . Loss of hair can be psychologically and emotionally distressing. It adds to the vulnerability of an individual further adding to morbidity and a poor quality of life.

A hereditary disorder called as Androgenetic Alopecia (AGA) is one of the most common form of hair loss in man as well women. The hair loss in this type of alopecia starts as early as 20 years of age, and is noticed in approximately 50% of men by the age of 50 years and on an average 50% of women over the course of lifetime. It usually starts as gradual loss of hair line in males which subsequently leads to complete baldness. In females, although hairline is retained, it causes generalised thinning of hair over the top of the head (Female pattern hair loss).

Multiple surgical and non-surgical modalities have been mentioned in the literature for the treatment of Androgenetic Alopecia. A new formulation called as QR678 has been recently introduced by Dr. Rinky Kapoor and Dr. Debraj Shome to overcome the hair loss due to Androgenetic Alopecia.

The product QR678 has got US patent in 2017 and Indian FDA approval in 2019. Dr Kapoor and Dr Shome have conducted the largest clinical trial showing the results of QR678 on patients with Androgenetic Alopecia. The results showing the efficacy have been published in the top American Journal in 2018. Before conducting the human clinical trial, the formulation was tested on animals to establish the concentration of multiple ingredients, safety, and the efficacy.

Recently a study was also conducted showing the efficacy of QR678 hair therapy over PRP treatment of Male Androgenetic Alopecia. We administered approximately 1.5 ml solution of QR678 in group A and PRP in group B on the scalp skin of the patients covering the visible areas of hair thinning and alopecia.

Platelet-rich plasma (PRP) is an autologous preparation of platelets in concentrated plasma. It is considered that growth factors released from platelets may act on stem cells in the bulge area of the follicles, stimulating the development of new follicles and promoting neovascularisation. However, it is cumbersome to draw patient’s blood at each session and it is difficult to standardise the entire procedure. It even requires extra armamentarium, in turn increasing the overall cost of the treatment.

Parameters like Hair pull test, Global Photographic assessment, Video microscopic assessment were done. The results were assessed at an interval of 6 months and follow-up was done after 1 year.

At the end of 6 months, it was observed that hair fall was reduced by 100% in QR678 group. The results were maintained over 1 year. The results with PRP group were inferior both in terms of reduction in hair fall as well as retention of hair at 1 year follow up.  The hair density, vellus hair density, terminal hair density, and shaft diameter were also significantly better in QR678 group (p<0.005) compared to PRP group.

The formulation of QR678 has been proved to be more beneficial for Male Androgenetic Alopecia (Male pattern hair loss) as compared to PRP or any other non -surgical treatment modality.

This is one of its kind formulation, which is not only safe, cost effective, efficacious and a comfortable procedure but the best part of the treatment is that the results are maintained  over a long period of time.